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2ABSTRACT
Huntington’s disease is caused by the expansion of a CAG repeat within exon 1 of the HTT 
gene, which is unstable, leading to further expansion, the extent of which is brain region and 
peripheral tissue specific. The identification of DNA repair genes as genetic modifiers of 
Huntington’s disease, that were known to abrogate somatic instability in Huntington’s 
disease mouse models, demonstrated that somatic CAG expansion is central to disease 
pathogenesis, and that the CAG repeat threshold for pathogenesis in specific brain cells 
might not be known. We have previously shown that the HTT gene is incompletely spliced 
generating a small transcript that encodes the highly pathogenic exon 1 HTT protein. The 
longer the CAG repeat, the more of this toxic fragment is generated, providing a pathogenic 
consequence for somatic expansion. Here, we have used the R6/2 mouse model to 
investigate the molecular and behavioural consequences of expressing exon 1 HTT with 90 
CAGs, a mutation that causes juvenile Huntington’s disease, compared to R6/2 mice carrying 
~200 CAGs, a repeat expansion of a size rarely found in Huntington’s disease patient’s 
blood, but which has been detected in post mortem brains as a consequence of somatic CAG 
repeat expansion. We show that nuclear aggregation occurred earlier in R6/2(CAG)90 mice 
and that this correlated with the onset of transcriptional dysregulation in these lines. 
Whereas in R6/2(CAG)200 mice, cytoplasmic aggregates accumulated rapidly and closely 
tracked with the progression of behavioural phenotypes and with end-stage disease. We 
find that aggregate species formed in the R6/2(CAG)90 brains have different properties to 
those in the R6/2(CAG)200 mice. Within the nucleus, they retain a diffuse punctate 
appearance throughout the course of the disease, can be partially solubilised by detergents 
and have a greater seeding potential in young mice. In contrast, aggregates from 
R6/2(CAG)200 brains polymerise into larger structures that appear as inclusion bodies. These 
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3data emphasise that a subcellular analysis, using multiple complementary approaches, must 
be undertaken in order to draw any conclusions about the relationship between HTT 
aggregation and the onset and progression of disease phenotypes.     
KEYWORDS: Huntington’s disease; polyglutamine; huntingtin aggregation and seeding; 
transcriptional dysregulation; somatic CAG instability
ABBREVIATIONS
AGERA = agarose gel electrophoresis for resolving aggregates; DTT = dithiothreitol; FRASE = 
FRET-based aggregate seeding assay; HRP = horse radish peroxidase; NES = nuclear export 
signal; NLS = nuclear localisation signal; PBS = phosphate buffer saline; PMSF = 
phenylmethylsulphonyl fluoride; polyQ = polyglutamine; qPCR = real-time quantitative PCR; 
SDS = sodium dodecyl sulphate. 
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4INTRODUCTION
Huntington’s disease is an inherited neurodegenerative disorder that manifests with 
psychiatric, motor and cognitive symptoms (Bates et al., 2015). The mutation is a CAG 
repeat expansion in exon 1 of the huntingtin gene (HTT) that results in an abnormally long 
polyglutamine (polyQ) tract in the huntingtin protein (HTT) (HDCRG, 1993). Individuals with 
less than 36 CAGs remain unaffected, those with 40 or more will develop the disease within 
a normal lifespan and those with 36 – 39 CAGs have an increasing chance of developing 
Huntington’s disease (Rubinsztein et al., 1996). CAG repeat expansions of approximately 65 
or more are likely to result in symptom onset in childhood or adolescence (Telenius et al., 
1993). Huntington’s disease causes widespread atrophy of the brain and results in 
prominent cell loss in the striatum, cortex and other brain regions (Vonsattel and DiFiglia, 
1998). HTT aggregation can be detected in the brain by antibody staining and occurs as 
nuclear inclusions and neuropil aggregates (DiFiglia et al., 1997; Gutekunst et al., 1999).
Although CAG repeat length is the major determinant of age of onset and disease 
progression, genetic and environmental modifiers also contribute (Wexler et al., 2004). CAG 
repeats are unstable in Huntington’s disease patient brains (Kennedy et al., 2003; 
Shelbourne et al., 2007; Gonitel et al., 2008) and somatic expansion in brain is correlated 
with an earlier disease onset (Swami et al., 2009). This somatic instability is recapitulated in 
mouse models of Huntington’s disease (Mangiarini et al., 1997), and is prevented in the 
absence of the mismatch repair genes Msh2, Msh3, Mlh1 and Mlh3 (Manley et al., 1999; 
Pinto et al., 2013; Tome et al., 2013). Therefore, the identification of six DNA repair genes as 
modifiers of the age of onset and / or progression of Huntington’s disease through genome-
wide association studies: FAN1, MSH3, MLH1, PMS1, PMS2 and LIG1 (GEM-HD, 2015; Lee et 
al., 2017; Moss et al., 2017; Ciosi et al., 2019; Flower et al., 2019; GeM-HD, 2019) underlined 
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5a causative role for somatic CAG instability in the pathogenesis of Huntington’s disease. It 
also suggested that the pathogenic repeat threshold in brain cells might be larger than that 
measured in blood and, if so, such a threshold is currently unknown.  
The HTT gene contains 67 exons, and we have previously shown that exon 1 does 
not always splice to exon 2 resulting in the production of a small transcript (Httexon1) that 
terminates at cryptic polyadenylation sites within intron 1. This occurs in knock-in mouse 
models (Sathasivam et al., 2013; Franich et al., 2019), where the level of incomplete splicing 
correlates with the appearance of disease phenotypes, and in Huntington’s disease post 
mortem brains and cell lines (Neueder et al., 2017). The Httexon1 transcript contains a stop 
codon at the beginning of intron 1 and is translated to produce the highly pathogenic exon 1 
HTT protein (Sathasivam et al., 2013; Neueder et al., 2018), by the same mechanism as 
occurs in R6/2 mice (Mangiarini et al., 1996). The extent of this incomplete splicing 
increases with increasing CAG repeat length, and therefore, the consequence of somatic 
CAG expansion in the HTT allele is the increased production of the pathogenic exon 1 HTT 
protein. 
The critical role that N-terminal HTT fragments play in the pathogenesis of 
Huntington’s disease is supported by the fact that when CAG repeat size and strain 
background are comparable, R6/2 and knock-in mice have highly comparable phenotypes at 
late-stage disease (Kuhn et al., 2007; Woodman et al., 2007; Sathasivam et al., 2010; 
Labbadia et al., 2011; Mielcarek et al., 2014; Mielcarek et al., 2015). Here, we have 
established a novel R6/2 line with 90 CAGs (R6/2(CAG)90), a mutation that causes juvenile 
Huntington’s disease, and conducted a molecular, immunohistochemical and behavioural 
comparison with R6/2 mice carrying approximately 200 CAGs (R6/2(CAG)200). We find that 
transcriptional dysregulation occurred earlier in R6/2(CAG)90 mice and correlated with the 
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6appearance of aggregated HTT in neuronal nuclei. However, behavioural phenotypes 
progressed faster in the R6/2(CAG)200 mice and this correlated with the accumulation of 
cytoplasmic aggregates. The length of the polyQ tract, which drives HTT aggregation in 
Huntington’s disease patient brains is unknown; and we show here that the HTT aggregates 
formed from the expanded polyQ tracts in these two models have different 
immunohistochemical and molecular properties. Our work demonstrates that correlations 
between HTT aggregation and disease phenotypes requires a subcellular analysis both at 
molecular and immunohistochemical levels.     
MATERIALS AND METHODS
Mouse Breeding and Maintenance
All procedures were performed in accordance with the Animals (Scientific Procedures) Act 
1986 and were approved by the University Ethical Review Panel. Hemizygous R6/2 mice 
were bred by backcrossing R6/2 males to (C57BL/6JOlaHsd x CBA/CaOlaHsd)F1 females 
(B6CBAF1/OlaHsd, Envigo, Netherlands). R6/2 and wild type mice were group housed 
dependent on gender, but genotypes were mixed within cages. The temperature was 
regulated at 21°C ± 1°C and animals were kept on a 12 h light / dark cycle. All animals had 
unlimited access to water and breeding chow (Special Diet Services, Witham, UK) and to 
standard cage environmental enrichment (bedding and play tube). Mouse brains were 
rapidly dissected, frozen in liquid nitrogen and stored at -80 °C. 
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7Genotyping, CAG repeat sizing, and Somatic Instability Analysis
Mice were genotyped and the CAG repeat size was measured by PCR of tail-tip DNA as 
previously described (Sathasivam et al., 2010). The mean CAG repeat size for all R6/2(CAG)90 
mice was 90.55 ± 1.79, and for all R6/2(CAG)200 mice was  210.24 ± 7.2 (±S.D.). For somatic 
instability analysis, 50 ng DNA was amplified using HD3F FAM 5'-
CCTTCGAGTCCCTCAAGTCCTT-3' and HD5 5’-CGGCTGAGGCAGCAGCGGCTGT-3' primers with 
Amplitaq Gold and GC enhancer (Thermo Fisher Scientific). Cycling conditions were 95C for 
10 min, 35 cycles of (95C for 30 sec, 65C for 30 sec, 72C for 90 sec) and 72C for 10 min. 
Samples were run on an ABI 3730xl Genetic Analyser with MapMarker ROX 1000 internal 
size standards and analyzed using GeneMapper v5 software (Thermo Fisher Scientific). The 
extent of repeat instability was assessed by the somatic instability index (Lee et al., 2010) 
and expansion index (GeM-HD, 2019), relative to heart, using a custom R script and 
confirmed manually. Inclusion threshold for instability and expansion indices was 10% of 
modal peak height.
Behavioural and Phenotype Assessment
Body Weight. Body weight was monitored weekly, prior to grip strength and rotarod 
assessment, and recorded to the nearest 0.1 g.
Grip Strength. Forelimb grip strength was measured using a Grip Strength Meter (San Diego 
Instruments, CA, USA) at the following ages: R6/2(CAG)90 at 6, 12, 16, 20, and 24 weeks of 
age, and R6/2(CAG)200 at 4, 7, 9, 11 and 13 weeks of age. Mice were held by the base of the 
tail and allowed to grip the wire, they were gently pulled horizontally away from the 
apparatus until the wire was released and the maximum tension (g) was recorded. The mice 
were tested five times and the average performance of the best three trials was used 
https://mc.manuscriptcentral.com/braincom
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spirit between trials.
Rotarod performance. Mice were tested on a standard Ugo Basile 7650 rotarod (Linton 
Instrumentation, UK), with the modification of a smooth rubber coating over the rotating 
rod as previously described (Hockly et al., 2003). At the start of each trial, mice were 
acclimatized to the apparatus by being placed on the rotating rod at 4 rpm for 20 s. 
Following acclimatization, the rod progressively accelerated from 4 rpm to 40 rpm over a 
period of 5 min. Latency (s) for mice to fall from the rod was recorded. For the first test 
session (at 6 weeks of age for R6/2(CAG)90, or 4 weeks of age for R6/2(CAG)200), rotarod 
performance was tested for three trials per day for four consecutive days. For all later 
sessions, performance was tested for three trials per day for three consecutive days. In both 
cases, the data from the last two days were used for the analysis. The apparatus was 
thoroughly cleaned with 70% industrial methylated spirit between testing each mouse.
RNA extraction and real-time quantitative PCR 
Total RNA was isolated from individual brain regions using the RNeasy mini kit according to 
the manufacturer’s instructions, which includes a DNase I treatment to remove genomic 
DNA (Qiagen). RNA was quantified using a Nanodrop-1000 spectrophotometer (Thermo 
Fisher Scientific) and stored at −80°C. cDNA was synthesised using random hexamers with 
an MMLV RT-ase kit (Invitrogen). Real-time quantitative PCR (qPCR) was then performed 
using the CFX96 C1000 real-time thermal cycler (Bio-Rad). Housekeeping reference genes 
were for cortex: Atp5b, Canx, Rpl13a and Ubc, striatum: Atp5b, Eif4a2, and Ubc, cerebellum: 
Atp5b, Rpl13a, and Ubc (Primer Design). Primer sequences and probes used are summarized 
in Supplementary Table 1. The levels of gene expression were determined by normalizing to 
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2−ΔΔCt method (Livak and Schmittgen, 2001; Benn et al., 2008).
Antibodies – The antibodies used for western blotting, Seprion-ligand ELISA, AGERA, filter-
trap, and immunohistochemistry, together with their respective dilutions, are summarized 
in Supplementary Table 2. Because of the difference in the length of the polyQ tracts 
between the two mouse lines, antibodies with a polyglutamine epitope were avoided, 
except for the detection of aggregates after formic acid antigen retrieval.  
Cytoplasmic and nuclear fractionation 
Cytoplasmic and nuclear fractions were prepared as previously described (Davies et al., 
1999), their protein concentration was determined using the PierceTM BCA protein assay kit 
(Thermo Fisher Scientific), and their purity was determined by immunoblotting using anti-
histone H3 and anti-α-tubulin antibodies.
Western blotting 
Half brains were homogenized (Polytron PT1200E) in ice-cold IGEPAL RIPA buffer [150 mM 
NaCl, 50 mM Tris-HCl pH 8.0, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS] with 1 mM 
PMSF, 1 mM DTT and cOmplete protease inhibitor cocktail tablets (Roche). Protein 
concentration was determined using the PierceTM BCA protein assay kit (Thermo Fisher 
Scientific). For immunoblotting, 20 - 40 μg of total protein in Laemmli loading buffer was 
denatured at 85 °C for 5 min and separated by 10-, 12-, or 15% Criterion TGX Stain-free SDS-
PAGE (Bio-Rad) and blotted onto 0.45 μm nitrocellulose membrane (Bio-Rad) by submerged 
transfer apparatus (Bio-Rad) in [25 mM Tris base, 192 mM glycine, 20% v/v methanol]. For 
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immunoblotting of cytoplasmic and nuclear fractions, either 25 μg of cytoplasm or 12.5 μg 
of nuclei in Laemmli loading buffer was used. Membranes were blocked for 1 h at room 
temperature in 3% non-fat dried milk in PBST [PBS, 0.1% Tween-20], and then incubated 
overnight with gentle agitation at 4°C with the primary antibody (in PBST with 1% non-fat 
dried milk). For chemiluminescent detection, blots were washed three times in PBST for 5 
min, probed with HRP-linked secondary antibodies (in PBST with 0.5% non-fat dried milk) for 
1 h at room temperature and washed three times in PBST. Protein was detected by 
chemiluminescense (Clarity, Bio-Rad) according to the manufacturer's instructions. The 
signals were captured on a ChemiDoc Touch Imaging System (Bio-Rad). 
SeprionTM-Pad ELISA
HTT aggregates were captured in Seprion-ligand coated plates (Microsens, PADPCB1 SEP1–
01) as described (Sathasivam et al., 2010). For individual brain regions, a 2.5% (w/v) total 
protein lysate was prepared in ice-cold IGEPAL RIPA buffer [150 mM NaCl, 50 mM Tris-HCl 
pH 8.0, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS] with 1 mM PMSF, 1 mM DTT, and 
cOmplete protease inhibitor cocktail tablets (Roche), by homogenizing three times for 30 s 
in Lysing matrix D tubes (MP Biomedicals) in a Fast-Prep-24TM instrument (MP Biomedicals), 
and 15 μL was loaded per well. For cytoplasmic and nuclear fractions, samples were 
prepared as described, and either 25 μg cytoplasm or 5 μg nuclei diluted in 15 μL ice-cold 
IGEPAL RIPA buffer was loaded per well.
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FRET-based aggregate seeding (FRASE) assay
For cortical brain tissue, a 10% (w/v) total protein lysate was prepared by homogenising in 
ice-cold FRASE buffer [10 mM Tris-HCl pH 7.4, 0.8 M NaCl, 1 mM EDTA, 10% sucrose, 0.25 
U/mL benzonase], with cOmplete protease inhibitor tablets (Roche), in Precellys® CK14 
lysing kit tubes (Precellys® 24 Homogenizer). The homogenate was incubated for 1 h at 4°C 
on a rotating wheel and protein concentration was determined using the PierceTM BCA 
protein assay kit (Thermo Fisher Scientific). The FRASE assay was performed and evaluated 
according to the method previously described (Ast et al., 2018) using 2.5 µg of crude lysate 
per replicate.
Agarose gel electrophoresis for resolving aggregates (AGERA)  
For AGERA gels (Weiss et al., 2008), 1.5 g agarose (Bio-Rad) was dissolved in 100 ml 375 mM 
Tris-HCl, pH 8.8, then once fully dissolved, SDS was added to a final concentration of 0.1%. 
Gels were gently poured into 10 cm Flowgen BioscienceTM gel trays (8 mm thick), and 
allowed to set (20-well comb, 2 mm thick). For immunoblotting, either 100 μg cytoplasm or 
25 μg nuclei was diluted in non-reducing Laemmli buffer [150 mM Tris–HCl pH 6.8, 33% 
glycerol, 1.2% SDS and bromophenol blue], denatured at 95°C for 5 min, and loaded 
alongside a Hi-MarkTM HMW pre-stained standard (Invitrogen). Samples were run in ultra-
pure Tris/Glycine/SDS [25 mM Tris, 192 mM Glycine, 0.1% SDS] running buffer (National 
Diagnostics) at 100 V until the dye front reached the bottom of the gel, and blotted onto 
0.45 μm nitrocellulose membrane by submerged transfer apparatus as described for 
western blotting above.
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Filter-trap retardation assay of SDS insoluble aggregates
Half brains were homogenized in ice-cold IGEPAL RIPA buffer and protein concentration 
determined exactly as described for western blotting. For filter-trap, two WhatmanTM 3 mm 
and one 0.2 μm cellulose acetate membrane filter (Whatman) were equilibrated in [PBS 
0.1% SDS] and assembled onto a 96-well MiniFold-1TM dot-blot system (Whatman). Next, 
wells were filled and washed twice with 250 μL [PBS 0.1% SDS] and aspirated under vacuum. 
Then, after filling each well with 200 μL [PBS 0.1% SDS], 10 μg of protein lysate was loaded 
per well dissolved in 50 μL [PBS 0.1% SDS]. Finally, under vacuum, samples were aspirated, 
and subsequently washed three times in 250 μL [PBS 0.1% SDS]. Once disassembled, 
cellulose acetate membranes were blocked for 1 h at room temperature in 3% non-fat dried 
milk in PBST [PBS, 0.2% Tween-20], and processed exactly as described for western blotting.
Immunohistochemistry
Mice were transcardially perfusion fixed with 4% paraformaldehyde (Pioneer Research 
Chemical Ltd). Brains were removed and further post-fixed for 6 h at 4°C before 
cryoprotection with gradient steps of 20% and 30% sucrose in 0.01 M PBS (Sigma). Once the 
brains reached equilibrium (had sunk to the bottom of the sucrose solution) they were 
washed in PBS, embedded in OCT (CellPath Ltd) and stored at -80°C. Coronal brain sections 
were cut at 30 μm on a cryostat and stored free floating at -20°C in tissue protective 
solution (30% ethylene glycol, 25% glycerol and 0.05% sodium azide in PBS) until staining.
Sections were washed in PBS before endogenous peroxide activity was quenched 
using 1% hydrogen peroxide (H2O2) in PBS for 30 min followed by three washes in PBS. Prior 
to immunostaining, non-specific binding was blocked for 1 h using 10% normal goat serum 
(Sigma) in PBST (0.5% tritonX-100 (Sigma) in PBS). MW8 primary antibody was applied in 
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fresh blocking solution overnight at 4°C. Sections were washed three times in PBS before 
application of the biotinylated secondary antibody (1:500, Vector, Peterborough, UK) for 2 
h. Sections were washed three times in PBS before signal amplification using Elite ABC 
reagent. Biotinylated antibody staining was visualised using Sigma FastDAB (0.5 mg/ml) in 
PBS and activated with H2O2. Sections were treated with DAB solution for 20 s and rapidly 
washed with ice-cold PBS to stop the reaction. The sections were washed a further three 
times with ice-cold PBS to remove the DAB solution completely before mounting on glass 
slides. To counterstain nuclei, slides were exposed to thionin (Sigma) in (40 mM sodium 
acetate, 90 mM acetic acid pH 4.3) for 2 min. Slides were then processed through 70%, 90% 
and 100% alcohols and xylene before cover-slipping with DPX mountant (Sigma).
Prior to 4H7H7 primary antibody application, antigen-retrieval was used to expose 
aggregation buried epitopes. Sections were treated three times with 88% formic acid (Alfa 
Aesar) for 10 min followed by three washes in PBS after each treatment. Then, sections 
were treated with 0.5 M ethanolamine (Sigma) in PBS (pH 9.5, blocking excess reacting 
aldehyde sites) for 1 h with the addition of ascorbic acid (EDQM) to a concentration of 5 mM 
for the final 10 min (reducing Schiff bases). Sections were rinsed in PBS three times and 
blocked three times with PBST for 10, 30 and 10 min. Biotinylated 4H7H7 (1:3000) was then 
applied in fresh PBST overnight at 4°C. Sections were washed three times in PBS before 
signal amplification using Elite ABC reagent (Vector). Sections were washed three times in TI 
buffer [0.05 M Tris pH 7.4, 0.05 M Imidazole (Sigma) in PBS]. Signals were amplified using 
the Tyramide Signal Amplification kit (Perkin Elmer) according to the manufacturer’s 
recommendations and then washed three times in PBST prior to a second application of 
Elite ABC reagent.
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Histological images were obtained using a Ziess AxioSkop2 plus microscope fitted 
with a Ziess AxioCam HRc colour camera. Images were recorded using Ziess AxioVision 4.7.
Statistical analysis
Data were screened for outliers using ROUT or Grubb’s Test (GraphPad software), and any 
outliers were removed before between-group comparisons. Statistical analysis was 
performed with SPSS (v22 and v26) and R using two-tailed Student’s t-test, one-way ANOVA, 
two-way ANOVA or GLM ANOVA, with Bonferroni post hoc tests as indicated. Graphs were 
prepared using GraphPad Prism (v6 and v7) and R. P-values less than 0.05 were considered 
statistically significant.
DATA AVAILABILITY
The authors confirm that all the data supporting the findings of this study are available 
within the article and its Supplementary material. Raw data will be shared by the 
corresponding author on request. The custom repeat instability R script can be accessed and 
run online on request.
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RESULTS
The CAG repeat has been maintained at approximately 200 CAGs in our R6/2 colony for 
more than 15 years. To generate a line with a shorter CAG repeat expansion, R6/2 mice 
were recovered from cryopreserved sperm (Jackson laboratory; stock initially deposited by 
James Olson). The three resultant pups included one wild type female, one R6/2 male and 
one R6/2 female, both of which had CAG repeats of 90 CAGs. The line was established by 
backcrossing R6/2(CAG)90 males to (CBA/Ca x C57BL/6J)F1 females. We had previously 
shown that CAG repeats in R6 lines of mice expand when bred through the male line, and 
contract when bred from females (Mangiarini et al., 1997). Therefore, we transmitted the 
(CAG)90 allele through the female line for six generations with the intention of reducing the 
CAG repeat length further, but the CAG repeat in this R6/2 allele proved to be very stable, 
whether bred through the male or female germ lines.  
Behavioural phenotypes progress more slowly in R6/2 mice with (CAG)90 than with 
(CAG)200
To determine the course of disease in the R6/2(CAG)90 mice, progressive changes in body 
weight, grip strength and rotarod performance were recorded. The R6/2(CAG)200 data 
presented here were not collected at the same time and are included to allow the reader to 
draw comparisons in disease progression between the two lines. R6/2(CAG)90 and 
R6/2(CAG)200 mice were sacrificed at 24 and 15 weeks of age respectively at which point, 
they had reached comparable end-stage disease.     
Body weight was measured weekly from 6 to 24 weeks of age for R6/2(CAG)90 mice 
and 4 to 15 weeks of age for R6/2(CAG)200 mice. In both cases, R6/2 mice stopped gaining 
weight and then lost weight relative to wild type littermates and the decrease in weight was 
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more pronounced in males than in females: R6/2(CAG)90 males (Fig. 1A) [F(age x 
genotype)16,306 = 10.125, p < 0.001], R6/2(CAG)90 females (Fig. 1B) [F(age x genotype)16,306 = 
3.247, p < 0.001], R6/2(CAG)200 males (Fig. 1C) [F(age x genotype)11,167 = 6.590, p < 0.001] 
and R6/2(CAG)200 females (Fig. 1D) [F(age x genotype)11,141 = 2.681, p = 0.004].  
 Forelimb grip strength was measured on weeks 6, 12, 16, 20 and 24 for R6/2(CAG)90 
and on weeks 4, 7, 9, 11 and 13 for R6/2(CAG)200 mice. In males, grip strength decreased for 
R6/2 as compared to wild type mice: R6/2(CAG)90 males (Fig. 1E) [F(age x genotype)4,85 = 
34,810, p < 0.001] and R6/2(CAG)200 males (Fig. 1G) [F(age x genotype)4,70 = 9.305, p < 
0.001]. In females, the grip strength of wildtype and R6/2 mice only changed differently with 
age for the R6/2(CAG)90 females (Fig. 1F) [F(age x genotype)4,88 = 3.781, p = 0.007] but not 
for R6/2(CAG)200 females (Fig. 1H) [F(age x genotype)4,59 = 1.567, p = 0.193]. However, grip 
strength was different between wild type mice and R6/2(CAG)200 females (Fig. 1H) 
[F(genotype)1,59 = 29.841, p < 0.001] and the R6/2(CAG)200 female grip strength changed 
with age (Fig. 1H) [F(age)4,59 = 37.802, p < 0.001].
To assess changes in balance and co-ordination, mice were tested for their ability to 
walk on an accelerating rotarod during weeks 6, 12, 16, 20 and 24 for R6/2(CAG)90 and 
during weeks 4, 8, 10, 12 and 14 for R6/2(CAG)200 mice. There was no difference in the 
latency to fall between R6/2(CAG)90 and wild type littermates at 6 weeks of age (Fig. 1I) 
[F(genotype)1,186 = 1.887, p = 0.178] or R6/2(CAG)200 and wild type littermates at 4 weeks 
(Fig. 1J) [F(genotype)1,163 = 1.468 p = 0.234]. In both cases, performance deteriorated with 
disease progression: R6/2(CAG)90 (Fig. 1I) [F(age x genotype)4,186 = 3.447, p = 0.010] and 
R6/2(CAG)200 (Fig. 1J) [F(age x genotype)4,163 = 4.225, p = 0.003].  
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Transcriptional dysregulation presents earlier in R6/2(CAG)90 than in R6/2(CAG)200 mice
These physiological and behavioural measures indicated that disease onset occurred later 
and progressed more slowly in the R6/2(CAG)90 as compared to the R6/2(CAG)200 mice. 
Transcriptional dysregulation is a well-defined molecular phenotype that has been 
extensively studied in post mortem brains (Hodges et al., 2006) and mouse models of 
Huntington’s disease (Langfelder et al., 2016). To determine when transcriptional 
dysregulation could first be detected, we used real-time quantitative PCR (qPCR) to measure 
the levels of ‘genes of interest’, known to be highly dysregulated in Huntington’s disease 
mouse models (Benn et al., 2008), in the striatum, cortex and cerebellum of R6/2(CAG)90 
and R6/2(CAG)200 mice at 4 and 8 weeks of age (Fig. 2).   
There was a dramatic reduction in the levels of the striatal genes: Cnr1, Darpp32, 
Drd2, Pde10a and Penk1 in R6/2(CAG)90 mice at 4 weeks of age, at which point they 
remained at wild type levels in R6/2(CAG)200 mice (Fig. 2A). By 8 weeks, all five genes were 
decreased to greater than 50% of wild type levels and dysregulated to a comparable extent 
in both the R6/2(CAG)90 and R6/2(CAG)200 lines (Fig. 2B). A similar pattern was evident for 
the cortical genes, with the expression levels of BdnfIV, Pgam2, Grm2, Hrh3 and Hrt1a 
decreasing at an earlier age in R6/2(CAG)90 than R6/2(CAG)200 mice (Fig 2C,D). For the 
cerebellum, changes in Igbp5, Kcnk2 and Pcp4 occurred earlier in R6/2(CAG)90 mice (Fig. 
2E,F) but this could not be determined for Nr4a2 and Uchl1 as measurement of expression 
levels at 4 and 8 weeks of age did not capture the age at which dysregulation first occurred 
for these two genes (Fig. 2E,F). Therefore, dysregulation of striatal, cortical and cerebellar 
transcripts occurred earlier in R6/2(CAG)90 than R6/2(CAG)200 mice, in contrast to the 
physiological and behavioural phenotypes which had a later age of onset. 
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Huntingtin aggregation can be detected earlier in the brains of R6/2(CAG)90 than 
R6/2(CAG)200 mice
We next used the Seprion ELISA assay to compare HTT aggregation levels in R6/2(CAG)90 and 
R6/2(CAG)200 lysates from striatum, cortex, hippocampus and cerebellum at 2, 4 and 8 
weeks of age (Fig. 3A-D). In all brain regions from the R6/2(CAG)90 mice, aggregation could 
be detected as early as 2 weeks of age, and the aggregate load remained higher at 4 weeks 
than for R6/2(CAG)200 mice. However, by 8 weeks, the level of HTT aggregation was 
comparable between the two R6/2 lines (Fig. 3A-D). We next compared the aggregation 
levels in brain between the R6/2(CAG)90 and R6/2(CAG)200 mice at end-stage disease, at 24 
and 14 weeks of age respectively. These were relatively comparable for the cortex and 
cerebellum, but end-stage aggregate levels were higher in the striatum and hippocampus 
from 14 week old R6/2(CAG)200 mice than for the R6/2(CAG)90 line (Fig. 3E-H). Therefore, 
HTT aggregates formed at an earlier age in the R6/2(CAG)90 lines but accumulated faster in 
the brains of the R6/2(CAG)200 mice.   
Next, cortical lysates from 4, 8, 16 and 24 week old R6/2(CAG)90 and 4, 8, and 14 
week old R6/2(CAG)200 mice were separated by SDS-PAGE to assess the soluble and 
aggregated state of the exon 1 HTT protein (Fig. 3I,J). The migration of exon 1 HTT is 
retarded by expanded polyQ tracts with the consequence that exon 1 HTT with 90Q 
migrated at approximately 45 kDa and with 200Q at approximately 90 kDa. In both cases, 
the level of soluble exon 1 HTT decreased with disease progression as it was recruited into 
aggregates. At 14 weeks of age, soluble exon 1 HTT could no longer be detected in the 
cortex of R6/2(CAG)200 mice, whereas in R6/2(CAG)90 at 24 weeks, trace amounts were still 
present (Fig. 3J). In keeping with the Seprion ligand ELISA data, aggregated HTT could still be 
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detected more readily in the stacking gel at 4 weeks of age in R6/2(CAG)90 lysates than in 
R6/2(CAG)200 lysates (Fig. 3I,J). 
CAG repeats undergo somatic instability in R6/2 mice to varying extents that are  
brain region and tissue specific (Mangiarini et al., 1997). Examination of the western blots 
(Fig. 3.I,J), together with those in Supplementary Fig. 1, suggested that the size of the exon 1 
HTT protein might be slightly larger in older R6/2(CAG)90 brains as compared to those from 
younger mice. To investigate whether this might be due to somatic instability, we extracted 
DNA from available tissues: brainstem, cerebellum, liver, tibialis anterior, gastrocnemius, 
quadriceps and heart from R6/2(CAG)90 mice at 24 weeks of age and R6/2 (CAG)200 mice at 
14 weeks of age and prepared GeneMapper capillary electrophoresis traces of the CAG 
repeat profile (Fig. 4 A,B). Consistent with our previous data, we found greater instability in 
brainstem than cerebellum (Fig. 4 and Supplementary Fig. 2). Similarly, the absence of CAG 
instability in the three muscles and heart, in both the R6/2(CAG)90 and R6/2(CAG)200 mice, 
was consistent with previous data (Mangiarini et al., 1997). However, unlike R6/2(CAG)200 
mice in which, as expected, the CAG repeat was very unstable in liver, we only detected a 
modest level of instability in this tissue in R6/2(CAG)90 mice (Fig. 4 and Supplementary Fig. 
2). These data predict that the CAG expansions in specific brain regions in older mice would 
be larger than the 90 CAGs originally measured in tail DNA prior to weaning.  
The level of expression of the R6/2 transgene is higher in the brains of R6/2(CAG)90 than 
R6/2(CAG)200 mice
To further investigate the mechanism by which aggregation occurs earlier in the 
R6/2(CAG)90 compared to the R6/2(CAG)200 line, we measured the level to which the R6/2 
transgene was expressed by qPCR. At two weeks of age, the R6/2 transgene was expressed 
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at between 2.5 and 3 fold greater in the striatum, cortex and cerebellum from R6/2(CAG)90 
as compared to R6/2(CAG)200 mice (Supplementary Fig. 3A). Expression in the cortex 
decreased from approximately 2.5 fold higher to between 1.5 and 2 fold higher at between 
4 and 14 weeks of age (Supplementary Fig. 3B). The levels of endogenous Htt were 
equivalent to that in wild type mice for both the R6/2(CAG)90 and R6/2(CAG)200 mice over 
this period (Supplementary Fig. 3C). 
Formation of huntingtin aggregates in neuronal nuclei occurs earlier in R6/2(CAG)90 
compared to R6/2(CAG)200 mice
To investigate the temporal and spatial appearance of HTT aggregates in the brains of 
R6/2(CAG)90 and R6/2(CAG)200 mice, sections were immunoprobed with the MW8 antibody, 
which detects the C-terminus of the exon 1 HTT protein and readily detects HTT aggregates 
(Fig. 5). At 4 weeks of age, the level of immunostaining was greater in the R6/2(CAG)90 
sections for both cortex (Fig. 5A) and striatum (Fig. 5B). In contrast, there was very little 
signal in the R6/2(CAG)200 cortex (Fig. 5A), and almost none detected in the R6/2(CAG)200 
striatum (Fig. 5B). In the R6/2(CAG)90 hippocampus, immunostaining could be detected 
throughout the pyramidal layer (CA1-CA3) and dentate gyrus, whereas in the R6/2(CAG)200 
animals, immunostaining was only prominent in the CA1 region (Fig. 5C and Supplementary 
Fig. 7A). In all cases, the immunostaining was predominantly nuclear, appearing as a diffuse 
signal in R6/2(CAG)90 brains, whereas a more punctate inclusion pattern was present in 
R6/2(CAG)200 sections (Fig. 5A-C). At 8 weeks of age, the nuclear staining pattern in 
R6/2(CAG)90 sections remained diffuse, whereas in R6/2(CAG)200 sections the inclusions had 
increased in both number and size (Fig. 5A-C). To illustrate the location of nuclei, sections 
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from a 8 week old R6/2(CAG)200 mice were immunoprobed with MW8 and counterstained 
with thionin (Supplementary Fig. 4). 
To investigate the nature of the diffuse nuclear immunostain, we then 
immunoprobed R6/2(CAG)90 and R6/2(CAG)200 sections from mice at 4 and 8 weeks of age 
with the 4H7H7 antibody that detects polyglutamine peptides. No signal was detected since 
the polyglutamine epitopes were buried in HTT aggregates (Supplementary Fig. 5). However, 
upon treatment with formic acid, which exposed the polyglutamine epitopes (rendering 
them available for antibody binding), the diffuse nuclear stain was now observed. 
Therefore, this represented an aggregated form of HTT, and was particularly evident in the 
brain sections from R6/2(CAG)90 mice (Supplementary Fig. 5).  
Cytoplasmic aggregates accumulate more rapidly in the brains of R6/2(CAG)200 as 
compared to R6/2(CAG)90 mice
Cytoplasmic aggregates could be seen in cortical and striatal sections from 
R6/2(CAG)200 mice at 8 weeks of age (Fig. 5 A,B), but appeared to be comparatively absent 
from the equivalent sections from R6/2(CAG)90 mice. To investigate the presence of 
cytoplasmic aggregates in more detail, we focussed on the hilus, that lies within the cleft of 
the dentate gyrus within the hippocampus, an area in which cytoplasmic aggregates are 
particularly abundant in R6/2(CAG)200 mice. Aggregated HTT accumulated in the neuronal 
nuclei of the pyramidal cells from the CA1 to the CA3 as well as the granule cells of the 
dentate gyrus in R6/2(CAG)90 brains at 4 weeks of age, at which time, aggregates were only 
present in the CA1 region of R6/2(CAG)200 brains (Fig. 6A). At this age, cytoplasmic 
aggregates were not apparent in the hilus in either of the R6/2 lines upon immunoprobing 
with MW8. At 8 weeks of age, cytoplasmic aggregates were abundant in the hilus of 
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R6/2(CAG)200 brains but were relatively sparse in the comparable regions from R6/2(CAG)90 
brains (Fig. 6A, Supplementary Fig. 5D). We next compared HTT aggregation in older mice: 
16 and 24 weeks for R6/2(CAG)90 and 14 weeks for R6/2(CAG)200 mice, where 24 weeks and 
14 weeks both represent end-stage disease. The extent of cytoplasmic aggregation in the 
cortex, striatum and hippocampus (both dorsal to the CA1 pyramidal layer and in the hilus) 
was greater in end-stage brains from R6/2(CAG)200 than R6/2(CAG)90 mice (Fig. 6B)
To further investigate the distribution of soluble and aggregated HTT in the nucleus 
and cytoplasm, we prepared nuclear and cytoplasmic fractions from R6/2(CAG)90 
hemispheres at 4, 8, 16 and 24 weeks of age and from R6/2(CAG)200 hemispheres at 4 and 8 
weeks of age. The nuclear and cytoplasmic fractions were western blotted and 
immunoprobed with the S830 antibody (Fig. 7A). Soluble exon 1 HTT was detected in the 
cytoplasmic fractions and the levels decreased with age for both R6/2 lines, as the soluble 
protein was recruited into aggregates (Fig. 7A). Consistent with our previous data, soluble 
exon 1 HTT could not be detected in the nuclear fraction from R6/2(CAG)200 mice. However, 
we were able to detect a weak signal corresponding to soluble exon 1 HTT in the 
R6/2(CAG)90 nuclear fraction (Fig. 7A). Examination of the stacking gel showed that, 
consistent with the immunohistochemical analysis (Fig. 5), nuclear aggregation could be 
detected at a younger age in R6/2(CAG)90 than in R6/2(CAG)200 mice (Fig. 7A). This was 
further confirmed by Seprion ELISA, showing that the level of aggregated HTT was greater in 
the R6/2(CAG)90 nuclei at 4 weeks of age but then accumulated rapidly so that by 8 weeks of 
age the levels in the R6/2(CAG)200 nuclei, as measured by the Seprion ELISA were greater 
(Fig. 7B). The cytoplasmic fractions cannot be used to study aggregation, as a considerable 
proportion of the cytoplasmic aggregates are lost during the preparation of the fractions, as 
indicated by the lack of aggregate signal in the cytoplasmic stacking gel (Fig. 7A). 
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Aggregated HTT in R6/2(CAG)90 and R6/2(CAG)200 mouse brains has different molecular 
properties
In order to further investigate differences in the HTT aggregates formed in the brains of the 
R6/2(CAG)90 and R6/2(CAG)200 brains, we separated the nuclear fractions from 4 and 8 week 
old mice by agarose gel electrophoresis for resolving aggregates (AGERA) (Fig. 8A). At 4 
weeks of age, the degree of aggregation was not only greater in R6/2(CAG)90 mice but the 
migration was more compact than in R6/2(CAG)200 mice. At 8 weeks of age, the level of 
aggregation was more comparable, but the migration of the aggregates was still visually 
more compact in R6/2(CAG)90 samples. 
We then used cortical samples to investigate HTT aggregate properties over the 
entire disease course of both R6/2 lines. The Seprion ELISA (Fig. 3B,F) and 
immunohistochemical analyses (Fig. 5A and Supplementary Fig. 5A) had been consistent in 
demonstrating that the aggregate load was greater in the R6/2(CAG)90 cortex at 4 weeks of 
age. At 8 weeks, although the Seprion ELISA assay suggested that aggregate levels were 
relatively comparable (Fig. 3A-H), the immunohistochemical staining pattern with MW8 was 
very different: appearing as a diffuse signal in the R6/2(CAG)90 nuclei and as inclusion bodies 
in the R6/2(CAG)200 nuclei. The filter retardation assay traps larger aggregates on filters, 
whilst allowing smaller aggregates to wash through (Scherzinger et al., 1999). Filtration of 
cortical lysates through cellulose acetate filters showed that aggregates from the 
R6/2(CAG)200 brains were trapped on the filters at both 8 and 14 weeks of age, whereas this 
was not the case from R6/2(CAG)90 brains (Fig. 8B). At all ages, up to 24 weeks of age, 
aggregates from the R6/2(CAG)90 cortices were never trapped on the cellulose acetate 
membrane (Fig. 8B). Finally, we used the FRASE assay (Ast et al., 2018) to assess the seeding 
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competence of aggregates from the same cortices as had been used for the filter-trap assay 
(Fig. 8C-E). Aggregates from the R6/2(CAG)90 cortices were already seeding competent by 2 
weeks of age (Fig. 8C,D), this had increased at 4 weeks but then did not increase any further 
up to late-stage disease at 24 weeks of age (Fig. 8D). The seeding competence of the 
R6/2(CAG)200 cortical lysates was similar to wild type at 2 weeks of age (Fig. 8C,E) and then 
increased considerably between 4 and 8 weeks (Fig. 8C,E). Therefore, the cortical aggregates 
from 2 and 4 week old R6/2(CAG)90 mice were smaller and had a greater seeding 
competence than those from R6/2(CAG)200 mice. 
DISCUSSION
Here, we have used R6/2 transgenic mice expressing an exon 1 HTT transgene with (CAG)90 
and (CAG)200 repeats to investigate the effects of polyglutamine expansions on the 
molecular and immunohistochemical properties of HTT aggregates and their phenotypic 
consequences. We showed that nuclear aggregation occurred earlier in R6/2(CAG)90 mice 
and that this correlated with the onset of transcriptional dysregulation. However, 
cytoplasmic aggregates accumulated more rapidly in the R6/2(CAG)200 mice, and more 
closely tracked with the progression of behavioural phenotypes and with end-stage disease. 
We found that aggregate species formed in the R6/2(CAG)90 brains have different properties 
to those in the R6/2(CAG)200 mice. Within the nucleus, they retained a diffuse punctate 
appearance throughout the course of the disease, and could be partially solubilised by 
detergents. There were a greater number of aggregate seeds in the brains of younger 
R6/2(CAG)90 mice than those from R6/2(CAG)200. Aggregates from R6/2(CAG)90 brains were 
more compact on AGERA gels and, unlike aggregates from R6/2(CAG)200 brains, did not 
become trapped after filtration through cellulose acetate membranes as the disease 
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progressed. These data emphasise that understanding the relationship between HTT 
aggregation and the onset and progression of disease phenotypes in Huntington’s disease 
mouse models, requires a subcellular analysis using multiple complimentary approaches.    
Soluble HTT and its N-terminal fragments can only be detected in the cytoplasm on 
western blots in R6/2, BACHD and HdhQ150 mice (Benn et al., 2005; Landles et al., 2010; Gu 
et al., 2015), and therefore, we had not expected to find that an exon 1 HTT fragment 
migrated as a soluble protein in the nuclear fraction from the R6/2(CAG)90 brains. We have 
interpreted this as having been released from HTT aggregates for the following reason. The 
first 17 amino acids of HTT contain a very potent nuclear export signal (NES) (Cornett et al., 
2005; Zheng et al., 2013), which effectively expels soluble exon 1 HTT from the nucleus in 
transgenic mice (Benn et al., 2005). This endogenous NES is potent and was shown to 
override an exogenous nuclear localisation sequences (NLS), both in cell culture (Cornett et 
al., 2005) and in vivo (Benn et al., 2005), with the consequence that, despite the addition of 
an NLS, an exon 1 HTT protein with 20 glutamines was cytoplasmic in transgenic mice (Benn 
et al., 2005). In contrast, HTT proteins with polyQ tracts in the mutant range accumulate in 
the nucleus because they form detergent insoluble aggregates. In keeping with this, the 
addition of an NLS to a HTT protein containing an expanded polyQ tract accelerates the 
appearance of aggregates in the nucleus, and drives all of the mutant HTT into these nuclear 
aggregate structures (Schilling et al., 2004; Benn et al., 2005; Gu et al., 2015), which can be 
solubilised with formic acid (Landles et al., 2010; Gu et al., 2015). Therefore, we infer that, 
unlike R6/2(CAG)200, the R6/2(CAG)90 brains contain an aggregate species in the nucleus, 
from which soluble HTT can be released upon exposure to mild detergents in the sample 
preparation.   
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Transcriptional dysregulation is a well characterised molecular phenotype for 
Huntington’s disease that has been extensively studied in mice (Luthi-Carter et al., 2000; 
Langfelder et al., 2016) and post mortem brains (Hodges et al., 2006), demonstrating that 
mice usefully replicate this phenotype (Kuhn et al., 2007). Here, we have monitored the 
expression levels of specific transcripts, reproducibly altered in the brains of Huntington’s 
disease mouse models (Kuhn et al., 2007; Langfelder et al., 2016), as markers of 
transcriptional dysregulation. At 4 weeks of age, all striatal, cortical and some cerebellar 
transcripts were dysregulated in R6/2(CAG)90, but not in R6/2(CAG)200 mice. Therefore, the 
onset of transcriptional dysregulation correlated with the appearance of HTT aggregation 
and not with the presence of soluble exon 1 HTT which would have been shuttling between 
the nucleus and cytoplasm in both R6/2 lines. It was striking that the level of transcriptional 
dysregulation in both the striatum and cortex was comparable between R6/2(CAG)90 and 
R6/2(CAG)200 mice at 8 weeks of age, although the immunoprobing with MW8 revealed 
quite different nuclear structures: a diffuse signal for R6/2(CAG)90 and an inclusion body for 
R6/2(CAG)200.   
The accumulation of cytoplasmic aggregates was much faster in R6/2(CAG)200 brains 
and correlated with disease progression. In fact, cytoplasmic aggregates remained relatively 
sparse in R6/2(CAG)90 brain regions, even at end-stage disease. In a previous study, end-
stage disease occurred much earlier, and the range of neurological phenotypes was more 
extensive in R6/2 mice with aggregate pathology in both the nucleus and cytoplasm, as 
compared to those with comparable aggregation occurring in the nucleus only (Benn et al., 
2005). In keeping with this, heterozygosity for HDAC4, a cytoplasmic protein that interacts 
with HTT (Mielcarek et al., 2013; Federspiel et al., 2019), delayed aggregation in the 
cytoplasm, improved behavioural phenotypes, and delayed end-stage disease in R6/2 mice, 
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whilst the levels of nuclear aggregation and transcriptional dysregulation were unchanged 
(Mielcarek et al., 2013).  
The work presented in this study contributes to a larger data set showing that the 
relationship between CAG repeat length and disease progression in R6/2 mice is complex, 
with phenotypes generally worsening with increasing CAG repeat length up to 
approximately 150 CAGs, after which phenotypes improve as the CAG repeat length 
increases further (Dragatsis et al., 2009; Morton et al., 2009; Cummings et al., 2012; Morton 
et al., 2019). The level of huntingtin expression at both RNA and protein levels was lower in 
R6/2 mice with expansions in 400 CAG range as opposed to 150 CAGs (Dragatsis et al., 
2009), consistent with the prediction that unusual DNA structures formed by super-long 
CAG repeats might impair transcription (Duzdevich et al., 2011). As CAG repeats expanded 
beyond 150 CAGs, the proportion of cytoplasmic HTT aggregates increased dramatically, 
presumably because exon 1 HTT with super-long CAG expansions can no longer diffuse into 
the nucleus. Therefore, the onset and progression of the phenotype is determined by the 
consequences of a given CAG repeat length on transgene expression, protein aggregation 
and the subcellular localisation of aggregate pathology. 
A number of factors could influence the difference in the subcellular location of the 
aggregates in the R6/2(CAG)90 and R6/2(CAG)200 lines. The kinetics of HTT aggregation are 
concentration and polyQ length dependent (Scherzinger et al., 1999), and given that we 
found that the transgene is more highly expressed in the R6/2(CAG)90 mice, both of these 
factors will influence the differential rate of aggregate formation between the R6/2(CAG)90 
and R6/2(CAG)200 lines. (1) The probability of aggregates forming in a specific subcellular 
location will depend upon local exon 1 HTT concentrations, and possibly, how these are 
influenced by interactions with other proteins and the local proteostasis network. (2) The 
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concentration of exon 1 HTT in the nucleus will be determined by whether it is small enough 
to diffuse across the nuclear membrane, a size determined by the polyQ repeat length, 
which at the cellular level might have increased through the somatic expansion of the CAG 
repeat. Somatic expansions are more likely to result in the exclusion of exon 1 HTT from the 
nucleus in the R6/2(CAG)200 than the R6/2(CAG)90 mice. (3) Once aggregates have formed in 
one subcellular location, the recruitment of soluble exon 1 HTT into these aggregates will 
deplete the levels available for aggregation elsewhere. 
HTT aggregates formed in the nuclei of R6/2(CAG)90 mice could be distinguished 
from those in R6/2(CAG)200 mice by immunohistochemistry with MW8, appearing as a 
diffuse nuclear signal, as compared to a discrete inclusion body, throughout the course of 
disease in these two lines. This diffuse pattern of nuclear aggregation is similar to that 
previously published for knock-in mice with 92 glutamines (Wheeler et al., 2000), although 
at the time of publication, it was not understood that this represented an aggregated form 
of HTT. Our work demonstrates that the simple correlation of HTT aggregate load in the 
brain with disease phenotypes is likely to be misleading, and that this must be performed at 
a subcellular level. Here we have identified distinct contributions from nuclear and 
cytoplasmic aggregates to molecular and behavioural phenotypes, and this should be 
extended to distinguish the consequences of aggregates in other subcellular regions e.g. the 
synapse. We have shown that aggregates formed from HTT proteins with different 
polyglutamine expansions also have different molecular properties as defined by filter 
retardation, gel electrophoresis and aggregate seeding potential. More sophisticated 
approaches will now be required to understand what structures these represent, and to 
distinguish the effects they might have on cellular function. Whilst we do not understand 
the impact of somatic CAG repeat expansion in generating the pathogenic length of 
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polyglutamine tracts in Huntington’s disease patient brains, it is important that we 
understand the properties of HTT proteins with a range of polyQ expansions.    
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FIGURE LEGENDS
Figure 1. Behavioural and physiological phenotypes progress more slowly in R6/2(CAG)90 
than R6/2(CAG)200 mice.
(A-D). Failure to gain body weight occurred later in (A) R6/2(CAG)90 males and (B) 
R6/2(CAG)90 females than in (C) R6/2(CAG)200 males and (D) R6/2(CAG)200 females 
respectively. (E-H) Reduction in fore-limb grip strength progressed more slowly in (E) 
R6/2(CAG)90 males and (F) R6/2(CAG)90 females than in (G) R6/2(CAG)200 males and (H) 
R6/2(CAG)200 females. A statistically significant reduction in grip strength occurred at 12 
weeks of age for R6/2(CAG)90 and 11 weeks of age for R6/2(CAG)200 for both genders of each 
genotype. Discrepancies in the wild type grip strength between the R6/2(CAG)90 and 
R6/2(CAG)200 datasets are because the data were collected on different machines by 
different operators at different times. (I, J) Rotarod performance, as compared to that of 
wild type littermates, deteriorated more slowly in (I) R6/2(CAG)90 mice than in their (J) 
R6/2(CAG)200 counterparts. The R6/2(CAG)200 data were extracted from the analysis 
published in Bobrowska et al. 2012 PLOS ONE 7, e34805. Discrepancies in the latency to fall 
between the wild type data sets are because the data were collected using different 
machines by different operators at different times. Wild type (CAG)90 (n = 20),  R6/2(CAG)90 
(n = 17 - 20), wild type (CAG)200 (n = 14 - 18),  R6/2(CAG)200 (n = 16 - 19). Statistical analysis 
was GLM ANOVA with Bonferroni post hoc correction *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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Figure 2. Striatal, cortical and cerebellar genes of interest were dysregulated earlier in 
R6/2(CAG)90 than R6/2(CAG)200 mice.
(A, B) Comparison of the levels of striatal transcripts, as measured by qPCR, between 
R6/2(CAG)90 and R6/2(CAG)200 mice at (A) 4 weeks and (B) 8 weeks of age. R6/2(CAG)90 
transcript levels were decreased compared to those of wild type littermates at 4 weeks of 
age, whereas the R6/2(CAG)200 and wild type levels were comparable. At 8 weeks of age, the 
transcripts were decreased to similar levels in both R6/2 lines. (C, D) Comparison of the 
levels of cortical transcripts, as measured by qPCR, between R6/2(CAG)90 and R6/2(CAG)200 
mice at (C) 4 weeks and (D) 8 weeks of age. R6/2(CAG)90 transcript levels were decreased 
compared to those of wild type littermates at 4 weeks of age, whereas the R6/2(CAG)200 and 
wild type levels were comparable. At 8 weeks of age, the Pgam2, Grm2 and Hrh3 transcripts 
were also decreased in the R6/2(CAG)200 mice, whereas BdnfIV and Hrt1a, were still 
expressed at levels similar to wild type. (E, F) Comparison of the levels of cerebellar 
transcripts, as measured by qPCR, between R6/2(CAG)90 and R6/2(CAG)200 mice at (E) 4 
weeks and (F) 8 weeks of age. At 4 weeks of age, R6/2(CAG)90 Igfbp5, Kcnk2, and Pcp4 
transcript levels were dysregulated compared to those of wild type littermates, whereas the 
R6/2(CAG)200 and wild type levels were comparable. At 8 weeks of age, all transcripts were 
dysregulated to similar levels in both R6/2 lines. n = 8 / genotype (4 male and 4 female). 
Statistical analysis was one-way ANOVA with Bonferroni post hoc correction ***p ≤ 0.001. 
The test statistic, degrees of freedom and p values for the ANOVA are provided in 
Supplementary Table 3. 
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Figure 3. Huntingtin aggregates were detected earlier in the brains of R6/2(CAG)90 than 
R6/2(CAG)200 mice. 
(A-D) Seprion ligand ELISA analysis of aggregated HTT in the (A) striatum, (B) cortex, (C) 
hippocampus and (D) cerebellum of R6/2(CAG)90 and R6/2(CAG)200 mice at 2, 4 and 8 weeks 
of age. Aggregated HTT was detected at 2 weeks of age in all brain regions from R6/2(CAG)90 
mice but not until 4 weeks in R6/2(CAG)200 mice. In all brain regions the level of HTT 
aggregation was higher in R6/2(CAG)90 mice than in R6/2(CAG)200 mice at 4 weeks of age. By 
8 weeks of age, the level of HTT aggregation was comparable between R6/2(CAG)90 and 
R6/2(CAG)200 mice for all brain regions. (E-H) Seprion ligand analysis of aggregated HTT in 
the (E) striatum, (F) cortex, (G) hippocampus and (H) cerebellum of R6/2(CAG)90 and 
R6/2(CAG)200 mice from 8 weeks of age until end-stage disease at 24 and 14 weeks of age 
respectively. (A-D) n = 6 / genotype. (E-H) n = 8 / genotype. The absorbance values cannot 
be compared between (A-D) and (E-H) as these experiments were not performed at the 
same time. Statistical analysis was two-way ANOVA with Bonferroni post hoc correction 
***p ≤ 0.001. The test statistic, degrees of freedom and p values for the ANOVA are 
provided in Supplementary Table 4. (I, J) Western blot analysis of soluble and aggregated 
exon 1 HTT protein in brain lysates from R6/2(CAG)90 mice at 4, 8, 16 and 24 weeks of age 
and from R6/2(CAG)200 mice at 4, 8 and 14 weeks of age, immunoprobed with either (I) 4C9 
or (J) MW8 antibodies. ATP5B was used as a loading control. Aggregated HTT was prominent 
in the stacking gel for R6/2(CAG)90 mice at 4 weeks, but not from R6/2(CAG)200 mice until 8 
weeks of age. The migration of soluble exon 1 HTT was retarded by the expanded polyQ 
tracts and the levels of this soluble protein diminished with age in both lines as they were 
recruited into aggregates. The full-sized blots for the loading controls are shown in 
Supplementary Fig. 12. WT = wild type.
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Figure 4. Comparison of somatic CAG instability in tissues from R6/2(CAG)90 and 
R6/2(CAG)200 mice. 
Capillary electrophoresis traces for (A) R6/2(CAG)90 mice at 24 weeks of age and (B) 
R6/2(CAG)200 mice at 14 weeks of age. The mode CAG repeat length is indicated at the top 
of the trace in red and the red dashed line helps to visualise the extent to which the CAG 
repeat has been somatically unstable during the lifespan of each mouse. Each vertical 
column shows the traces obtained from the tissues of a single mouse. The mean, standard 
deviation and data points for the instability and expansion indices of each tissue are 
illustrated in Supplementary Fig. 2, and the numerical values for these measures are listed 
on the right hand side of the tables (± SD) in (A) and (B). Somatic CAG instability was 
detected in the brain stem from both models, but was only prominent in the liver from the 
R6/2(CAG)200 mice. n = 5 / genotype. The mean CAG repeat size for R6/2(CAG)90 mice was 
93.11 ± 0.86 (SD) and for R6/2(CAG)200 mice was 190.53 ± 3.17 (SD). Statistical analysis was 
one-way ANOVA with Bonferroni post hoc correction, ***p ≤ 0.001. The test statistic, 
degrees of freedom and p values for the ANOVA are provided in Supplementary Table 5. WT 
= wild type.  
Figure 5. Aggregated HTT accumulated in neuronal nuclei in the brains of R6/2(CAG)90 at a 
younger age than in R6/2(CAG)200 mice 
The pattern of immunostaining detected with the MW8 antibody on brain sections from 
R6/2(CAG)90 and R6/2(CAG)200 mice at 4 and 8 weeks of age is shown for the (A) cortex, (B) 
striatum and (C) hippocampus. The location of the centre panel images in the brain sections 
is indicated in the adjacent thumbnails, and the position of the thumbnails within the tissue 
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section is illustrated in Supplementary Figs. 6 and 7. The wild type control sections are 
shown in Supplementary Figs. 8 and 9.  n = 3 / R6/2 genotype and n = 1 / wild type control. 
Centre panels, scale bar = 20 μm; thumbnails, scale bar = 200 μm.
Figure 6. Cytoplasmic HTT aggregates accumulate more rapidly in the brains of 
R6/2(CAG)200 than in R6/2(CAG)90 mice. 
The pattern of immunostaining detected with the MW8 antibody on brain sections from 
R6/2(CAG)90 and R6/2(CAG)200 mice. (A) The hippocampal hilus of the dentate gyrus at 4 and 
8 weeks of age. The location of the centre panel images in the brain sections is indicated in 
the adjacent thumbnails, and the position of the thumbnails within the tissue section is 
illustrated in Supplementary Figs. 6 and 7. The wild type control sections are shown in 
Supplementary Figs. 8 and 9.  (B) The cortex, striatum, CA1 region of the hippocampus and 
hilus at 16 and 24 weeks of age for the R6/2(CAG)90 and 14 weeks of age for the 
R6/2(CAG)200 mice. The location of the images from within the tissue sections is illustrated in 
Supplementary Fig. 10. The wild type control sections are shown in Supplementary Fig. 11. n 
= 3 / R6/2 genotype and n = 1 / wild type control.  (A) Centre panels, scale bar = 20 μm; 
thumbnails, scale bar = 200 μm. (B) scale bar = 20 μm.
Figure 7. Soluble exon 1 HTT was detected in the nuclear fraction from R6/2(CAG)90 but 
not from R6/2(CAG)200 brains. 
(A) Western blot of cytoplasmic and nuclear fractions from R6/2(CAG)90 and R6/2(CAG)200 
hemispheres at the ages indicated immunoprobed with the S830 antibody. A fragment that 
migrated as soluble exon 1 HTT was detected in the nuclear fraction of R6/2(CAG)90 but not 
R6/2(CAG)200 mice. S830 was used for the western blot presented here, as MW8 and 4C9 
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both detected cross-hybridising bands, which co-migrated with the R6/2(CAG)90 protein, 
making the presence of exon 1 HTT in the nuclear fraction harder to interpret. The purity of 
the nuclear and cytoplasmic fractions was indicated by immunoblotting with antibodies to 
α-tubulin and histone panH3 respectively. (B) Seprion ELISA analysis of HTT aggregation in 
nuclear fractions from R6/2(CAG)90 and R6/2(CAG)200 hemispheres at 4 and 8 weeks of age 
immunodetected with 4C9 or MW8 antibodies (n = 6 / genotype). Statistical analysis was 
two-way ANOVA with Bonferroni post hoc correction. ***p < 0.001. The test statistic, 
degrees of freedom and p values for the ANOVA are provided in Supplementary Table 6. WT 
= wild type.
Figure 8. HTT aggregates formed in R6/2(CAG)90 and R6/2(CAG)200 brains have different 
molecular properties. 
(A) Nuclear fractions from R6/2(CAG)90 and R6/2(CAG)200 hemispheres at 4 and 8 weeks of 
age were fractionated by AGERA and immunoprobed with either 4C9 or MW8 antibodies. 
(B) Cortical lysates from R6/2(CAG)90 and R6/2(CAG)200 mice were filtered through cellulose 
acetate filters and immunoprobed with either 4C9 or MW8 antibodies (wild type, n = 2; 
R6/2, n = 4 / genotype / age). (C) Quantification of mutant huntingtin seeding activity (HSA) 
in brain extracts from the R6/2(CAG)90, R6/2 (CAG)200 and wild-type control mice (n = 4 / 
genotype / age). Results for wild type mice are shown as an average Δt50 value. Cortical 
samples were from the same mice as had been used for the filter retardation assay in (B). 
(D) Effect of cortical homogenates from R6/2(CAG)90 and wild type mice at 2, 4, 8, 16 and 24 
weeks of age on the Ex1Q48-CyPet and –YPet (1:1 mixture, 1.2 μM) co-aggregation. (E) 
Effect of cortical homogenates from R6/2(CAG)200 and wild type mice at 2, 4, 8 and 14 weeks 
of age on the Ex1Q48-CyPet and –YPet (1:1 mixture, 1.2 μM) co-aggregation. Statistical 
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analysis was two-way ANOVA with Bonferroni post hoc correction. The test statistic, degrees 
of freedom and p values for the ANOVA are provided in Supplementary Table 7.  ***p < 
0.001. WT = wild type. 
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ABBREVIATED SUMMARY
Huntingtin (HTT) aggregates in the brains of Huntington’s disease transgenic mice with 90 or 
200 CAGs have different subcellular localisation, appearance and molecular properties. In 
these mice, aggregated HTT precedes transcriptional dysregulation in neuronal nuclei and 
the rate of disease progression correlated with the accumulation of aggregated HTT in the 
cytoplasm. 
https://mc.manuscriptcentral.com/braincom
